secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001493152-23-040049
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics Q3 revenue $2.5M, net loss $6.0M; receives $9.0M Gates Foundation grant
--------------------------------------------------------------------------------

- Revenue $2.5M, down from $5.1M in prior year due to declining COVID-19 test demand.
- Net loss of $6.0M ($0.20/sh) vs $1.4M loss ($0.04/sh) in prior year.
- Received $9.0M grant from Bill & Melinda Gates Foundation for TB test development on Co-Dx PCR platform.
- Expects EUA submission to FDA for Co-Dx PCR Pro platform and COVID-19 assay by year-end 2023.
- Cash and securities $63.4M as of Sept 30, 2023; repurchased 149,041 shares at $1.12 avg.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315223040049/0001493152-23-040049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315223040049/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer